Generate Biomedicines (NASDAQ:GENB) Shares Up 4.6% – Time to Buy?

Generate Biomedicines Inc (NASDAQ:GENB) shares rose 4.6% during mid-day trading on Monday . The company traded as high as $16.75 and last traded at $16.8550. Approximately 145,857 shares changed hands during trading, a decline of 78% from the average session volume of 667,813 shares. The stock had previously closed at $16.12.

Analyst Upgrades and Downgrades

GENB has been the subject of a number of recent analyst reports. HC Wainwright upped their price target on Generate Biomedicines from $16.00 to $25.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Weiss Ratings began coverage on shares of Generate Biomedicines in a research note on Tuesday, August 11th. They set a “sell (d)” rating on the stock. Wall Street Zen cut shares of Generate Biomedicines from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. Finally, Morgan Stanley upped their target price on shares of Generate Biomedicines from $20.00 to $22.00 and gave the company an “overweight” rating in a research note on Thursday, May 14th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $25.40.

Generate Biomedicines Stock Up 4.3%

The firm has a market cap of $2.16 billion and a PE ratio of -10.62. The business has a fifty day moving average price of $14.96.

Generate Biomedicines (NASDAQ:GENB) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.04). The business had revenue of $6.31 million during the quarter. On average, research analysts expect that Generate Biomedicines Inc will post -2.29 earnings per share for the current year.

Institutional Trading of Generate Biomedicines

A number of large investors have recently bought and sold shares of the business. California State Teachers Retirement System acquired a new stake in Generate Biomedicines during the 2nd quarter worth approximately $96,000. AXQ Capital LP bought a new position in Generate Biomedicines in the second quarter valued at approximately $218,000. Bank of New York Mellon Corp acquired a new position in shares of Generate Biomedicines in the second quarter valued at approximately $967,000. Braidwell LP bought a new stake in shares of Generate Biomedicines during the second quarter worth $55,398,000. Finally, Susquehanna International Group LLP bought a new stake in shares of Generate Biomedicines during the second quarter worth $196,000.

About Generate Biomedicines

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.